Previous Close | 2.2500 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 70.00 |
Expire Date | 2024-10-18 |
Day's Range | 2.0000 - 2.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 471 |
MADISON, Wis., May 22, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company’s work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To Wor
MADISON, Wis., May 21, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy’s (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy’s future infringement and false advertising.
There's been a notable change in appetite for Exact Sciences Corporation ( NASDAQ:EXAS ) shares in the week since its...